136 related articles for article (PubMed ID: 37916706)
21. Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy.
Faithfull S; Corner J; Meyer L; Huddart R; Dearnaley D
Br J Cancer; 2001 Dec; 85(12):1853-64. PubMed ID: 11747326
[TBL] [Abstract][Full Text] [Related]
22. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis comparing intensity-modulated radiotherapy with conformational radiotherapy (3D-RT) for prostate cancer in the brazilian health system.
Viani GA; Arruda CV; Oliveira R
Rev Assoc Med Bras (1992); 2021 Jun; 67(5):724-730. PubMed ID: 34550263
[TBL] [Abstract][Full Text] [Related]
24. Time-driven activity-based costing: a driver for provider engagement in costing activities and redesign initiatives.
McLaughlin N; Burke MA; Setlur NP; Niedzwiecki DR; Kaplan AL; Saigal C; Mahajan A; Martin NA; Kaplan RS
Neurosurg Focus; 2014 Nov; 37(5):E3. PubMed ID: 25363431
[TBL] [Abstract][Full Text] [Related]
25. National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project.
Defourny N; Perrier L; Borras JM; Coffey M; Corral J; Hoozée S; Loon JV; Grau C; Lievens Y
Radiother Oncol; 2019 Sep; 138():187-194. PubMed ID: 31319281
[TBL] [Abstract][Full Text] [Related]
26. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy.
Sethukavalan P; Cheung P; Tang CI; Quon H; Morton G; Nam R; Loblaw A
Can J Urol; 2012 Apr; 19(2):6165-9. PubMed ID: 22512958
[TBL] [Abstract][Full Text] [Related]
27. Cost of microvascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.
Julian GS; Accetturi Pititto LM; Miresashvili N; Broe Honoré J; Lopes Assis Coelho RC; Campos D
J Med Econ; 2021; 24(1):1002-1010. PubMed ID: 34344240
[TBL] [Abstract][Full Text] [Related]
28. Clinician-led improvement in cancer care (CLICC)--testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial--study protocol.
Brown BB; Young J; Smith DP; Kneebone AB; Brooks AJ; Xhilaga M; Dominello A; O'Connell DL; Haines M
Implement Sci; 2014 May; 9():64. PubMed ID: 24884877
[TBL] [Abstract][Full Text] [Related]
29. Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate.
Kobeissi BJ; Gupta M; Perez CA; Dopuch N; Michalski JM; Van Antwerp G; Gerber R; Wasserman TH
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):593-603. PubMed ID: 9486609
[TBL] [Abstract][Full Text] [Related]
30. What Is the Financial Impact of Orthopaedic Sequelae of Intravenous Drug Use on Urban Tertiary-care Centers?
Dwivedi N; Breslin MA; McDermott A; Lin S; Vallier HA; Tornetta P
Clin Orthop Relat Res; 2020 Oct; 478(10):2202-2212. PubMed ID: 32667752
[TBL] [Abstract][Full Text] [Related]
31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
32. Cancer Deaths due to Lack of Universal Access to Radiotherapy in the Brazilian Public Health System.
Mendez LC; Moraes FY; Fernandes GDS; Weltman E
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e29-e36. PubMed ID: 28988891
[TBL] [Abstract][Full Text] [Related]
33. [A microcost analysis of radiation therapy of localized prostate cancer].
Zemplényi AT; Mangel L; Kaló Z; Endrei D; Boncz I
Orv Hetil; 2016 Mar; 157(12):461-8. PubMed ID: 26971646
[TBL] [Abstract][Full Text] [Related]
34. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
35. Value-Based Healthcare in Urology: A Collaborative Review.
Reitblat C; Bain PA; Porter ME; Bernstein DN; Feeley TW; Graefen M; Iyer S; Resnick MJ; Stimson CJ; Trinh QD; Gershman B
Eur Urol; 2021 May; 79(5):571-585. PubMed ID: 33413970
[TBL] [Abstract][Full Text] [Related]
36. Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.
Glaser SM; Kalash R; Bongiorni DR; Roberts MS; Balasubramani GK; Jacobs BL; Beriwal S; Heron DE; Greenberger JS
In Vivo; 2018; 32(1):113-120. PubMed ID: 29275307
[TBL] [Abstract][Full Text] [Related]
37. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.
Panje CM; Dal Pra A; Zilli T; R Zwahlen D; Papachristofilou A; Herrera FG; Matzinger O; Plasswilm L; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):778-86. PubMed ID: 25986251
[TBL] [Abstract][Full Text] [Related]
38. Costs of standard and conformal photon radiotherapy in Austria.
Hohenberg G; Sedlmayer F
Strahlenther Onkol; 1999 Jun; 175 Suppl 2():99-101. PubMed ID: 10394412
[TBL] [Abstract][Full Text] [Related]
39. Cost minimisation analysis: kilovoltage imaging with automated repositioning versus electronic portal imaging in image-guided radiotherapy for prostate cancer.
Gill S; Younie S; Rolfo A; Thomas J; Siva S; Fox C; Kron T; Phillips D; Tai KH; Foroudi F
Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):e93-9. PubMed ID: 22694787
[TBL] [Abstract][Full Text] [Related]
40. Benchmarking dosimetric quality assessment of prostate intensity-modulated radiotherapy.
Senthi S; Gill SS; Haworth A; Kron T; Cramb J; Rolfo A; Thomas J; Duchesne GM; Hamilton CH; Joon DL; Bowden P; Foroudi F
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):998-1005. PubMed ID: 21310548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
